Objectives：The median effective concentration of ropivacaine in interscalene brachial plexus block for postoperative analgesia after arthroscopic rotator cuff repair(ARCR) has not been determined. Design: this is a prospective double blinded study. Method: This study was conducted on 40 patients with ASA grade I or II who had selective ARCR. A concentration of 10mL ropivacaine administered for the Interscalene brachial plexus block(ISBPB) was determined using the up-and-down sequential. The initial concentration of ropivacaine 0.3%. After a successful or unsuccessful postoperative analgesia, the concentration of ropivacaine was decreased or increased by 0.05% in the next patient, respectively. We defined successful postoperative analgesia as a visual analogue scale(VAS)score＜4 at rest or activity within initial 8 hours after ISBPB. VAS score≥4 was defined as unsuccessful analgesia. The analytic techniques of linear, linear-logarithmic, exponential regressions and centered isotonic regression were used to determine the EC50 of ropivacaine and the residual standard errors were calculated for the comparison of “goodness of fit” among the different models. Results: The concentration of local anesthetic ropivacaine administered ranged from 0.1% to 0.35%. The EC50 (95% confidence interval) from 4 different statistical approaches (linear, linear-logarithmic, exponential regressions and centred isotonic regression) were 0.207% (0.168%, 0.355%), 0.182% (0.165%, 0.353%), 0.196% (0.154%, 0.356%), and 0.163%, respectively. Among all of the 4 models, the exponential regression had the least residual standard error (0.0990). Conclusion: The EC50 derived from four statistical models for 10ml ropivacaine in ultrasound-guided interscalene brachial plexus block for postoperative analgesia was distributed in a narrow range of 0.163%–0.207%.

Background: This study aimed to determine the median effective analgesic concentration of 10mL ropivacaine in interscalene brachial plexus block for postoperative anesthesia in 50% of the patients (EC50). Method: This study was conducted on 30 patients with ASA grade I or II, who are planning to undergo proximal humerus fracture operation. A concentration of 10mL ropivacaine administered for the Interscalene brachial plexus was determined using the up-and-down sequential. The initial concentration of ropivacaine in the first patient to receive interscalene brachial plexus block(ISBPB) was 0.3%, After a successful or unsuccessful postoperative analgesia, the concentration of local anesthetic was decreased or increased, respectively, by 0.05% in the next patient. We defined successful postoperative analgesia as VAS score below 4 at rest within initial 8 hours after ISBPB. The analytic techniques of linear, linear-logarithmic, exponential regressions and centered isotonic regression were used to determine the EC50 of ropivacaine and the residual standard errors were calculated for the comparison of “goodness of fit” among the different models. Results: The concentration of ropivacaine administered ranged from 0.1% to 0.35%. The EC50 (95% confidence interval) from 4 different statistical approaches (linear, linear-logarithmic, exponential regressions and centred isotonic regression) were 0.222% (0.198%, 0.335%), 0.233% (0.215%, 0.453%), 0.223% (0.202%, 0.436%), and 0.232%, respectively. Among all of the 4 models, the linear regression had the least residual standard error (0.1676). Conclusion: The EC50 derived from four statistical models for 10ml ropivacaine in ultrasound-guided interscalene brachial plexus block for postoperative analgesia was distributed in a narrow range of 0.222%–0.233%.

Background: The median effective concentration of ropivacaine of ultrasound guided sciatic nerve block required for effective postoperative analgesia after arthroscopic anterior cruciate ligament reconstruction has not yet been determined. This study was to explore the median effective analgesic concentration of ropivacaine required to produce a successful sciatic nerve block for postoperative anesthesia. Method: A total of 29 patients underwent elective arthroscopic anterior cruciate ligament reconstruction were enrolled in study. A concentration of 20mL ropivacaine administered for the sciatic nerve was determined using the up-and-down sequential. The starting concentration was 0.2% in the first patient, the next patient would receive decremented 0.025% of ropivacaine if the prior patient’s postoperative visual analog pain score was less than 4 in the initial 8h. Otherwise, the following patient would received an incremental of 0.025% of ropivacaine. The analytic techniques of linear, linear-logarithmic, exponential regressions and centered isotonic regression were used to determine the EC50 of ropivacaine. Results: The concentration of ropivacaine administered ranged from 0.1% to 0.2%. The ED50 (95% confidence interval) from 4 different statistical approaches (linear, linear-logarithmic, exponential regressions and centred isotonic regression) were 0.129% (0.103%, 0.359%), 0.142% (0.112%, 0.347%), 0.113% (0.108%, 0.343%), and 0.115%, respectively. Among all of the 4 models, the exponential regression had the least residual standard error (0.2243). Conclusion: The EC50 derived from four statistical models for 20ml ropivacaine in ultrasound-guided sciatic nerve block for postoperative analgesia was distributed in a narrow range of 0.113%–0.142%, and the exponential regression was the model to best match the study data